Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1996 Jan;64(1):10–15. doi: 10.1128/iai.64.1.10-15.1996

Factors influencing secondary vibriocidal immune responses: relevance for understanding immunity to cholera.

G A Losonsky 1, J Yunyongying 1, V Lim 1, M Reymann 1, Y L Lim 1, S S Wasserman 1, M M Levine 1
PMCID: PMC173720  PMID: 8557325

Abstract

Although serum vibriocidal activity is used extensively as a marker of immunity to O1 Vibrio cholerae, there are limitations in this assay to detect instances of reexposure. We define the conditions operative in producing secondary vibriocidal responses in North American volunteers primed with either wild-type V. cholerae 1, 4, or 6 months later. Secondary serum vibriocidal responses occurred under two distinct secondary challenge conditions. The first occurred when secondary challenge produced a breakthrough in clinical protection. Following secondary exposure, 14 of 22 (64%) and 1 of 29 (3%) subjects with and without vibrio stool excretion, respectively, had secondary responses (P < 0.001); 5 of 6 (83%) and 10 of 45 (22%) subjects with or without diarrhea, respectively, mounted a secondary response (P = 0.006). The second condition occurred in the presence of full clinical protection but was dependent on the time interval between exposure. No subject (0 to 17) vaccinated with CVD 103-HgR and given homologous wild-type challenge within 4 months mounted a secondary vibriocidal response (P = 0.0009). The majority of the serum vibriocidal activity was of the immunoglobulin M (IgM) isotype, seen in 96 and 73% of subjects following primary and secondary exposure, respectively. Vibriocidal activity in the IgG fraction following primary and secondary exposures occurred with < or = 50% of volunteers; lipopolysaccharide (LPS)-specific IgG1 and IgG3 subclass responses supported the vibriocidal isotype data. However, following primary exposure, IgG4 LPS responses predominated, occurring in 81% of responding volunteers. These data suggest that, under certain conditions of secondary exposure to V. cholerae O1 antigens, when there is sufficient active local immunity present, there is a block of vibrio antigen resampling at the M cell level. We discuss the implications of and possible explanations for these findings.

Full Text

The Full Text of this article is available as a PDF (210.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahmed A., Bhattacharjee A. K., Mosley W. H. Characteristics of the serum vibriocidal and agglutinating antibodies in cholera cases and in normal residents of the endemic and non-endemic cholera areas. J Immunol. 1970 Aug;105(2):431–441. [PubMed] [Google Scholar]
  2. Black R. E., Levine M. M., Clements M. L., Young C. R., Svennerholm A. M., Holmgren J. Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin. Infect Immun. 1987 May;55(5):1116–1120. doi: 10.1128/iai.55.5.1116-1120.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Champsaur H., Iscaki S., Bernard O., Dodin A. Induction of Vibrio cholerae specific biliary antibodies after oral immunisation with a cholera cell-wall fraction. Lancet. 1985 Jun 1;1(8440):1276–1277. doi: 10.1016/s0140-6736(85)92347-5. [DOI] [PubMed] [Google Scholar]
  4. Chitnis D. S., Sharma K. D., Kamat R. S. Role of somatic antigen of Vibrio cholerae in adhesion to intestinal mucosa. J Med Microbiol. 1982 Feb;15(1):53–61. doi: 10.1099/00222615-15-1-53. [DOI] [PubMed] [Google Scholar]
  5. Clemens J. D., van Loon F., Sack D. A., Chakraborty J., Rao M. R., Ahmed F., Harris J. R., Khan M. R., Yunus M., Huda S. Field trial of oral cholera vaccines in Bangladesh: serum vibriocidal and antitoxic antibodies as markers of the risk of cholera. J Infect Dis. 1991 Jun;163(6):1235–1242. doi: 10.1093/infdis/163.6.1235. [DOI] [PubMed] [Google Scholar]
  6. Clements M. L., Levine M. M., Young C. R., Black R. E., Lim Y. L., Robins-Browne R. M., Craig J. P. Magnitude, kinetics, and duration of vibriocidal antibody responses in North Americans after ingestion of Vibrio cholerae. J Infect Dis. 1982 Apr;145(4):465–473. doi: 10.1093/infdis/145.4.465. [DOI] [PubMed] [Google Scholar]
  7. Field E. H., Noelle R. J., Rouse T., Goeken J., Waldschmidt T. Evidence for excessive Th2 CD4+ subset activity in vivo. J Immunol. 1993 Jul 1;151(1):48–59. [PubMed] [Google Scholar]
  8. Glass R. I., Svennerholm A. M., Khan M. R., Huda S., Huq M. I., Holmgren J. Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. J Infect Dis. 1985 Feb;151(2):236–242. doi: 10.1093/infdis/151.2.236. [DOI] [PubMed] [Google Scholar]
  9. Holmgren J., Svennerholm A. M. Mechanisms of disease and immunity in cholera: a review. J Infect Dis. 1977 Aug;136 (Suppl):S105–S112. doi: 10.1093/infdis/136.supplement.s105. [DOI] [PubMed] [Google Scholar]
  10. Kunimoto D. Y., Harriman G. R., Strober W. Regulation of IgA differentiation in CH12LX B cells by lymphokines. IL-4 induces membrane IgM-positive CH12LX cells to express membrane IgA and IL-5 induces membrane IgA-positive CH12LX cells to secrete IgA. J Immunol. 1988 Aug 1;141(3):713–720. [PubMed] [Google Scholar]
  11. Levine M. M., Black R. E., Clements M. L., Cisneros L., Nalin D. R., Young C. R. Duration of infection-derived immunity to cholera. J Infect Dis. 1981 Jun;143(6):818–820. doi: 10.1093/infdis/143.6.818. [DOI] [PubMed] [Google Scholar]
  12. Losonsky G. A., Tacket C. O., Wasserman S. S., Kaper J. B., Levine M. M. Secondary Vibrio cholerae-specific cellular antibody responses following wild-type homologous challenge in people vaccinated with CVD 103-HgR live oral cholera vaccine: changes with time and lack of correlation with protection. Infect Immun. 1993 Feb;61(2):729–733. doi: 10.1128/iai.61.2.729-733.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Mosley W. H., Ahmad S., Benenson A. S., Ahmed A. The relationship of vibriocidal antibody titre to susceptibility to cholera in family contacts of cholera patients. Bull World Health Organ. 1968;38(5):777–785. [PMC free article] [PubMed] [Google Scholar]
  14. Mosley W. H., Benenson A. S., Barui R. A serological survey for cholear antibodies in rural east Pakistan. 1. The distribution of antibody in the control population of a cholera-vaccine field-trial area and the relation of antibody titre to the pattern of endemic cholera. Bull World Health Organ. 1968;38(3):327–334. [PMC free article] [PubMed] [Google Scholar]
  15. Neoh S. H., Rowley D. The antigens of Vibrio cholerae involved in the vibriocidal action of antibody and complement. J Infect Dis. 1970 May;121(5):505–513. doi: 10.1093/infdis/121.5.505. [DOI] [PubMed] [Google Scholar]
  16. Nüsslein H. G., Spiegelberg H. L. Interleukin-4 induces both IgG4 and IgE secretion by peripheral blood B cells. J Clin Lab Anal. 1990;4(6):414–419. doi: 10.1002/jcla.1860040605. [DOI] [PubMed] [Google Scholar]
  17. Owen R. L., Pierce N. F., Apple R. T., Cray W. C., Jr M cell transport of Vibrio cholerae from the intestinal lumen into Peyer's patches: a mechanism for antigen sampling and for microbial transepithelial migration. J Infect Dis. 1986 Jun;153(6):1108–1118. doi: 10.1093/infdis/153.6.1108. [DOI] [PubMed] [Google Scholar]
  18. Pierce N. F., Kaper J. B., Mekalanos J. J., Cray W. C., Jr, Richardson K. Determinants of the immunogenicity of live virulent and mutant Vibrio cholerae O1 in rabbit intestine. Infect Immun. 1987 Feb;55(2):477–481. doi: 10.1128/iai.55.2.477-481.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. ROBBINS J. B., KENNY K., SUTER E. THE ISOLATION AND BIOLOGICAL ACTIVITIES OF RABBIT GAMMA M- AND GAMMA G-ANTI-SALMONELLA TYPHIMURIUM ANTIBODIES. J Exp Med. 1965 Aug 1;122:385–402. doi: 10.1084/jem.122.2.385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Sumaya C. V., Ench Y., Carrillo M. A., Pope R. M. Use of a simple separation column in detection of immunoglobulin M antibody to Epstein-Barr virus. J Clin Microbiol. 1984 Aug;20(2):298–299. doi: 10.1128/jcm.20.2.298-299.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Tacket C. O., Losonsky G., Nataro J. P., Cryz S. J., Edelman R., Kaper J. B., Levine M. M. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. J Infect Dis. 1992 Oct;166(4):837–841. doi: 10.1093/infdis/166.4.837. [DOI] [PubMed] [Google Scholar]
  22. Yamamoto T., Yokota T. Vibrio cholerae O1 adherence to human small intestinal M cells in vitro. J Infect Dis. 1989 Jul;160(1):168–169. doi: 10.1093/infdis/160.1.168. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES